全文获取类型
收费全文 | 25443篇 |
免费 | 2739篇 |
国内免费 | 482篇 |
专业分类
耳鼻咽喉 | 82篇 |
儿科学 | 703篇 |
妇产科学 | 497篇 |
基础医学 | 2580篇 |
口腔科学 | 596篇 |
临床医学 | 3136篇 |
内科学 | 2447篇 |
皮肤病学 | 158篇 |
神经病学 | 7884篇 |
特种医学 | 375篇 |
外国民族医学 | 2篇 |
外科学 | 1339篇 |
综合类 | 2817篇 |
现状与发展 | 6篇 |
预防医学 | 2072篇 |
眼科学 | 218篇 |
药学 | 1993篇 |
35篇 | |
中国医学 | 537篇 |
肿瘤学 | 1187篇 |
出版年
2024年 | 54篇 |
2023年 | 425篇 |
2022年 | 632篇 |
2021年 | 1079篇 |
2020年 | 1185篇 |
2019年 | 1067篇 |
2018年 | 1001篇 |
2017年 | 1042篇 |
2016年 | 1128篇 |
2015年 | 1025篇 |
2014年 | 1697篇 |
2013年 | 1942篇 |
2012年 | 1590篇 |
2011年 | 1542篇 |
2010年 | 1239篇 |
2009年 | 1177篇 |
2008年 | 1239篇 |
2007年 | 1256篇 |
2006年 | 1111篇 |
2005年 | 912篇 |
2004年 | 733篇 |
2003年 | 699篇 |
2002年 | 602篇 |
2001年 | 474篇 |
2000年 | 361篇 |
1999年 | 327篇 |
1998年 | 372篇 |
1997年 | 313篇 |
1996年 | 272篇 |
1995年 | 241篇 |
1994年 | 217篇 |
1993年 | 187篇 |
1992年 | 184篇 |
1991年 | 150篇 |
1990年 | 139篇 |
1989年 | 126篇 |
1988年 | 115篇 |
1987年 | 107篇 |
1986年 | 81篇 |
1985年 | 101篇 |
1984年 | 87篇 |
1983年 | 49篇 |
1982年 | 70篇 |
1981年 | 69篇 |
1980年 | 54篇 |
1979年 | 37篇 |
1978年 | 21篇 |
1977年 | 33篇 |
1976年 | 28篇 |
1968年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Background: Breast cancer (BC) is the most common malignant tumor in women, and its morbidity and mortality are
increasing each year, due to the lack of specific clinical symptoms in the early stage of BC, and the lack of diagnostic
methods for early breast cancer. Therefore, identifying an effective diagnostic method for early BC has become urgent.
Materials and Methods: Breast lesions with a histological diagnosis that were examined by ultrasonic elastography
(UE) in our department from June 2020 to December 2021 were reviewed. qRT-PCR was performed to measure
the expression levels of miR-144-5p and miR-26b-5p in the plasma of patients with BC. The receiver operating characteristics (ROC) curve and area under the curve (AUC) were used to investigate the potential diagnostic value of miR-
144-5p, miR-26b-5p and the elastographic score in BC. Results: The ultrasonic elastography score(UES) was found to
be significantly upregulated in BC compared with that in benign breast lesions, and the AUC, sensitivity and specificity
were 0.809, 0.717 and 0.806 for distinguishing BC from benign breast lesions, respectively. miR-144-5p and miR-26b-
5p were found to be upregulated in the plasma of BC patients, and miR-144-5p+miR-26b-5p had 0.781 sensitivity and
0.780 specificity for the diagnosis of BC. Furthermore, we found that the diagnostic performance of miR-144-5p and
miR-26b-5p combined with UES for BC had 0.913 sensitivity and 0.890 specificity. Conclusions: The combination of
plasma miR-144-5p, miR-26b-5p and UES has a very high clinical application value for the early detection of BC. 相似文献
2.
3.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
4.
5.
6.
7.
《中国现代医生》2020,58(11):135-138
目的 探讨齐拉西酮和奥氮平对于治疗早期精神分裂症的临床疗效及比较两者的安全性。方法 选取我院2017年9月~2019年2月收治的60例早期精神分裂症患者作为研究对象,采用数字随机法将所有患者分成对照组30例和观察组30例,对照组给予奥氮平治疗,观察组给予齐拉西酮治疗。2周为1个疗程,两组均进行8周4个疗程治疗。比较两组患者于治疗前和治疗后2、4、8周进行阳性和阴性症状量表(PANNS)评分,病情严重程度(SI)、疗效总评(GI)评分和不良反应。结果 治疗2周、4周后,两组患者的PANSS评分和SI、GI评分均较低于治疗前,但两组的PANSS评分和SI、GI评分比较,差异无统计学意义(P0.05);疗程结束后,观察组的患者PANSS评分和SI、GI评分均低于对照组,差异有统计学意义(P0.05);治疗期间,对照组的不良反应发生率高于观察组,差异有统计学意义(P0.05)。结论 对于治疗早期分裂症患者,齐拉西酮的长期治疗效果明显优于奥氮平,且安全可靠,值得临床上进一步推广。 相似文献
8.
目的分析早发型子痫前期应用低分子肝素期待治疗的临床效果。方法回顾分析2017-01—2018-12间在郑州大学第一附属医院产科终止妊娠的95例早发型子痫前期患者的临床资料。按终止妊娠前是否应用低分子肝素分为2组。对照组(47例)给予降压、解痉等治疗;观察组(48例)在对照组基础上加用低分子肝素。结果2组分娩孕周、妊娠延长时间、妊娠并发症发生率、新生儿出生体质量、新生儿窒息及胎儿宫内窘迫发生率、新生儿Apgar评分等,差异均无统计学意义(P>0.05)。结论对早发型子痫前期患者在常规治疗基础上短期应用低分子肝素,不能延长妊娠时间,不改善母婴结局。 相似文献
9.
10.